Clinical effectiveness secures BIMZELX as the first NICE expedited low risk fast track appraisal recommended treatment for moderate-to-severe plaque psoriasis1,2

NICE logo

BIMZELX is the first product to be recommended by NICE via a new approach to the fast-track appraisal process. The committee's findings can be found below.

NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2

BKZ effective banner
BKZ effective banner
BKZ response rates banner
BKZ response rates banner
Off

References

References

  1. Bimzelx Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. 2021. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis.
On

CHALLENGE EXPECTATIONS

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: August 2021
IE-P-BK-PSO-2100057